Last updated: 2026-10-14 21:16:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Zymeworks Inc. (ZYME) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $24.79, with a market capitalisation of $1.82B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $16.00 to $31.34. This page covers its latest market performance, valuation, price trends and company information.
$1.82B | |
$25.00 | |
$59.03 | |
$4.11 | |
$25.07 | |
404.82K | |
778.16K | |
-- | |
$31.34 | |
$16.00 | |
-- | |
-- |
Zymeworks Inc. (ZYME) is trading at $24.78 in after-hours trading as of 2026-10-14 20:16:00, down 1.18% ($0.30) from the regular-session close of $25.07.
After-hours trading shows how investors are pricing ZYME after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Zymeworks Inc. (ZYME) moved from $26.21 to $24.79, representing a decline of 5.43% ($1.42).
The stock traded between $24.60 and $27.02 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.60 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 57.3%
ZYME is currently trading at $24.79, placing it 57.3% of the way from its 52-week low of $16.00 to its 52-week high of $31.34. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 264 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Zymeworks Inc. (ZYME) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.